Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication

Journal of Infectious Diseases

Volumn 197, Issue 6, 2008, Pages 854-857

  Li, Zhao Hong ^a   Li, Chien Ming ^c   Ling, Pin ^a   Shen, Fang Hsiu ^a   Chen, Shih Heng ^a   Liu, Ching Chuan ^b   Yu, Chun Keung ^a   Chen, Shun Hua ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; CELL LINE; CELL LINE, TUMOR; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; MICE; MICE, INBRED ICR; RIBAVIRIN; VIRUS REPLICATION;

EID: 40949089777     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/527326     Document Type: Article

References (22)

1. Nolan MA, Craig ME, Lahra MM, et al. Survival after pulmonary edema due to enterovirus 71 encephalitis. Neurology 2003; 60:1651-6.
2. Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-35.
3. Chang LY, Huang LM, Gau SS, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226-34.
4. Shia KS, Li WT, Chang CM, et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 2002; 45:1644-55.
5. Kirsi JJ, North JA, McKernan PA, et al. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent. Antimicrob Agents Chemother 1983; 24:353-61.
6. Kishimoto C, Crumpacker CS, Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 1988; 12:1334-41.
7. Dumortier J, Ducos E, Scoazec JY, Chevallier P, Boillot O, Gagnieu MC. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006; 13:538-43.
8. Jairath S, Vargas PB, Hamlin HA, Field AK, Kilkuskie RE. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res 1997; 33:201-13.
9. McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997; 99:261-7.
10. Chong HT, Kamarulzaman A, Tan CT, et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol 2001; 49:810-3.
11. Remesar MC, Blejer JL, Weissenbacher MC, Nejamkis MR. Ribavirin effect on experimental Junin virus-induced encephalitis. J Med Virol 1988; 26:79-84.
12. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 1986; 6:285-97.
13. Wang YF, Chou CT, Lei HY, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 2004; 78:7916-24.
14. 12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother 2006; 50:1768-72.
15. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58:73-9.
16. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993; 37:532-9.
17. Saito Y, Escuret V, Durantel D, Zoulim F, Schinazi RF, Agrofoglio LA. Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon. Bioorg Med Chem 2003; 11:3633-9.
18. Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob Agents Chemother 1989; 33:2009-11.
19. Hosoya M, Mori S, Tomoda A, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2004; 48:4631-5.
20. Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol 2000; 145:1571-82.
21. Gunther S, Asper M, Roser C, et al. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro. Antiviral Res 2004; 63:209-15.
22. Liu ML, Lee YP, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 2005; 86:3263-9.